MSB 3.49% $3.04 mesoblast limited

WHO Solidarity Trial Results

  1. 70 Posts.
    lightbulb Created with Sketch. 82
    WHO released the data from their mega Solidarity trial of 4 potential Covid treatment options (including Remdesivir) which i have summarized below:

    • Study drugs were Remdesivir, Hydroxychloroquine, Lopinavir (fixed-dose combination with Ritonavir) and Interferon-β1a
    • COVID-19 patients were randomized equally between whichever study drugs were locally available and open control
    • 11,266 adults were randomized, with 2750 allocated Remdesivir, 954 Hydroxychloroquine, 1411 Lopinavir, 651 Interferon plus Lopinavir, 1412 only Interferon, and 4088 no study drug
    • Death rate ratios were: Remdesivir (301/2743 active vs 303/2708 control), Hydroxychloroquine (104/947 vs 84/906 control), Lopinavir (148/1399 vs 146/1372 control) and Interferon (243/2050 vs 216/2050 control)
    • Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay

    This study shows that there is currently no treatment that significantly reduces Covid-19 mortality. Note that the trial results do still need to be peer reviewed.
    Last edited by davos97: 17/10/20
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Mkt cap ! $1.847B
Open High Low Value Volume
$3.10 $3.11 $3.04 $8.226M 2.681M

Buyers (Bids)

No. Vol. Price($)
34 172266 $3.04

Sellers (Offers)

Price($) Vol. No.
$3.05 79425 30
View Market Depth
Last trade - 13.35pm 27/10/2020 (20 minute delay) ?
-0.110 ( 3.17 %)
Open High Low Volume
$3.10 $3.10 $3.04 910068
Last updated 13.55pm 27/10/2020 (live) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.